PDCD1 and neoplasm: To address the great unmet need for a treatment for anti-PD-1 antibody-resistant or -poorly responsive tumors, and to identify the preferred administration sequence of this combination therapy, we performed an experiment using a tumor model poorly responsive to an initial anti-PD-1 treatment.